Search clinical trials for: complement inhibitor

Total 70271 results

Chinese University of Hong Kong

Recruiting

Adjunctive Sirolimus and Oseltamivir Versus Oseltamivir Alone for Treatment of Influenza

Influenza

Hong Kong
HAE Global Registry Foundation

Recruiting

Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II (HGR)

Hereditary Angioedema Type I and II

Italy
Children's Hospital Medical Center, Cincinnati
National Institute of Neurological Disorders and Stroke (NINDS); National Center...

Recruiting

Mind and Body Approaches to Pain Reduction in Youth With Migraine

Migraine | Migraine Disorders | Headache | Headache, Migraine

United States
University of Nebraska

Recruiting

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

Rheumatoid Arthritis

United States
Pharming Technologies B.V.

Recruiting

C1 Inhibitor Registry in the Treatment of Hereditary Angioedema (HAE) Attacks

Hereditary Angioedema

Germany, Bulgaria, Croatia, Czechia, France, Hungary, Italy, North Macedonia, Poland, Slovakia, Norway, Slovenia, Sweden
BioCryst Pharmaceuticals

Active, not recruiting

Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies (APeX-A)

Hereditary Angioedema | HAE

France, North Macedonia, Poland, Korea, Republic of, Slovakia, South Africa, Czechia
Astellas Pharma Global Development, Inc.

Active, not recruiting

Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)

Stargardt's Macular Dystrophy

Italy, United States, Israel, United Kingdom, Germany, Spain, Hungary, France
Institut Pasteur de Dakar
Ministry of Health, Senegal; Fann Hospital, Senegal; Diamniadio Children Hospital... and other collaborators

Terminated

Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal (SEN-CoV-Fadj)

COVID-19

Senegal
Alexion Pharmaceuticals, Inc.

Active, not recruiting

A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Thailand, Korea, Republic of, United Kingdom, Israel, Czechia, Greece, Poland, Brazil, Japan, Canada, Malaysia
Shire
Takeda Development Center Americas, Inc.

Completed

A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor

Angioedema

United States, France, Netherlands, Spain, Hungary, Italy, Canada, Poland, Japan, Germany
Alexion Pharmaceuticals, Inc.

Terminated

Study of the Oral Factor D (FD) Inhibitor ALXN2050 in PNH Patients as Monotherapy

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, Turkey, United Kingdom, New Zealand, Korea, Republic of, Canada, Spain
CSL Behring

Active, not recruiting

Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks

Hereditary Angioedema

Australia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
University of Melbourne
Australian and New Zealand Intensive Care Research Centre; The Peter Doherty... and other collaborators

Active, not recruiting

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial (ASCOT)

SARS-CoV-2 Infection (COVID-19)

Australia
UCB Biopharma SRL

Active, not recruiting

An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors

Generalized Myasthenia Gravis

United States
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, South Africa, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portuga... and more
Alexion Pharmaceuticals, Inc.

Completed

ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Italy, United States, Taiwan, Thailand, Brazil, Russian Federation, United Kingdom, Belgium, Canada, Korea, Republic of, Poland, Malaysia, Japan, Czechia, Spain, Germany, Austria, France, Serbia, Mexico, Sweden, Estonia, Singapore, Ar... and more
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Canada, Australia, New Zealand, Singapore
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
InflaRx GmbH
Merck Sharp & Dohme LLC

Active, not recruiting

Non-comparative Study of IFX-1 Alone or IFX-1+Pembrolizumab in Patients With Locally Advanced or Metastatic cSCC.

SCC - Squamous Cell Carcinoma of Skin

United States, Spain, Germany, Belgium, France
BioCryst Pharmaceuticals

Terminated

Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN) (RENEW)

Immunoglobulin A Nephropathy | Membranous Nephropathy | Complement 3 Glomerulopathy

France, Italy, Spain, United Kingdom
University of Florida
National Center for Complementary and Integrative Health (NCCIH); Office of...

Completed

Resveratrol to Enhance Vitality and Vigor in Elders (REVIVE)

Physical Function | Mitochondrial Function

United States
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy (APPOINT-PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

China, Germany, Singapore, Korea, Republic of, Italy, United Kingdom, Malaysia, France
SINA Health Education and Welfare Trust
Horizon Pharmaceutical Pvt Ltd

Completed

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Hypoglycemic Agents | Empagliflozin

Pakistan
Pharming Technologies B.V.

Terminated

Prevention of Acute Kidney Injury in Patients With NSTEMI (AKI)

Non-ST Elevation Myocardial Infarction (NSTEMI)

Switzerland
Pharming Technologies B.V.

Completed

Safety of Ruconest in 2-13 Year Old Hereditary Angioedema (HAE) Patients

Hereditary Angioedema

Israel, Italy, United States, Czechia, Germany, Hungary, Poland, Romania, Slovakia, North Macedonia
Beker Laboratories

Completed

Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Long COVID.

Chronic Obstructive Pulmonary Disease | Asthma | Long COVID

Algeria
Yale University
National Center for Complementary and Integrative Health (NCCIH); Brain & Behavior...

Completed

Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD

ADHD

United States
Erasmus Medical Center
St. Antonius Hospital; Leiden University Medical Center; Amsterdam UMC

Completed

Personalized Targeted Immunomodulation in COVID-19 ARDS (COMODULATE)

COVID-19 Acute Respiratory Distress Syndrome

Netherlands
BioCryst Pharmaceuticals

Active, not recruiting

Berotralstat Treatment in Children With Hereditary Angioedema (APeX-P)

Hereditary Angioedema | Pediatric

Spain, Austria, Canada, France, Germany, Israel, Italy, Poland, Romania, United Kingdom
IVERIC bio, Inc.

Completed

A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)

Macular Degeneration | Geographic Atrophy

United States, Spain, France, Germany, Austria, Belgium, Israel, Poland, Canada, Italy, Estonia, Australia, United Kingdom, Hungary, Argentina, Brazil, Colombia, Croatia, Czechia, Latvia
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
IVERIC bio, Inc.

Completed

Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Macular Degeneration | Geographic Atrophy

United States, Israel, Estonia, Hungary, Latvia, Czechia, Croatia
Ophthotech Corporation

Completed

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Wet Age-related Macular Degeneration

United States, Hungary, Latvia
BioCryst Pharmaceuticals

Terminated

BCX9930 for the Treatment of PNH in Subjects Not Receiving Other Complement Inhibitor Therapy (REDEEM-2)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Malaysia, South Africa, Korea, Republic of
Pharvaris Netherlands B.V.

Active, not recruiting

Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II (HAE CHAPTER-1)

Hereditary Angioedema | Hereditary Angioedema Type I | Hereditary Angioedema Type II | Hereditary Angioedema Types I and II | Hereditary Angioedema Attack | Hereditary Angioedema With C1 Esterase Inhibitor Deficiency | Hereditary Angioedema - Type 1 | Hereditary Angioedema - Type 2 | C1 Esterase Inhibitor... and other conditions

United States, Poland, Germany, Austria, Bulgaria, Canada, Ireland, Italy, United Kingdom
Ophthotech Corporation

Withdrawn

ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)

Idiopathic Polypoidal Choroidal Vasculopathy

United States
Alexion Pharmaceuticals, Inc.

Completed

Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

Atypical Hemolytic Uremic Syndrome (aHUS)

United States, France, Spain, Taiwan, United Kingdom, Australia, Belgium, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Austria, Canada
Pharming Technologies B.V.

Completed

Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19

Confirmed Coronavirus Disease

United States
BioCryst Pharmaceuticals

Active, not recruiting

Long-term Safety of BCX9930 in Subjects With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria

United Kingdom, Hungary, France, Spain, Malaysia, South Africa, Korea, Republic of
Alexion Pharmaceuticals, Inc.

Completed

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Paroxysmal Nocturnal Hemoglobinuria

France, Italy, Spain, United States, Taiwan, Thailand, Korea, Republic of, Japan, Malaysia, Brazil, Germany, Israel, Czechia, Netherlands, Greece, United Kingdom, Canada, Poland
Ensysce Biosciences
National Institute on Drug Abuse (NIDA); Quotient Sciences

Completed

Pharmacokinetics of Oxycodone and PF614 Co-Administered With Nafamostat (MPAR-101)

Pharmacokinetics

United States
Takeda
Takeda Development Center Americas, Inc.

Completed

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

Angioedema

United States, Spain, Netherlands, Hungary, Italy, Canada, Germany, France, Japan, Poland
University Hospital, Montpellier

Terminated

The Role of the Coagulation Pathways in Recurrent Angioedema (Angiocoag)

Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency

France
Washington State University
National Center for Complementary and Integrative Health (NCCIH); Office of...

Active, not recruiting

Evaluating the Pharmacokinetics and Drug Interaction Potential of the Botanical Dietary Supplement Cinnamon

Interaction Drug Food

United States
Jagiellonian University

Completed

Letrozole add-on in the Treatment of Cesarean Scar Pregnancy

Cesarean Scar Pregnancy

Poland
Cedars-Sinai Medical Center
OneLegacy Foundation

Active, not recruiting

Berinert (C1INH) vs Placebo for DGF/IRI

Chronic Kidney Diseases | End Stage Renal Disease

United States
Amgen

Completed

A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications

Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

United States
Wonju Severance Christian Hospital

Enrolling by invitation

The Safety of Nafamostat Mesylate for Patients With High Risk Bleeding Undergoing Hemodialysis: A Pilot Study (Nafamostat)

Bleeding | Dialysis; Complications

Korea, Republic of
Georgetown University
University of Maryland, Baltimore; National Center for Complementary and Integrative... and other collaborators

Completed

Mechanisms of Probiotics and Antibiotic-Associated Diarrhea (OURBIOTIC)

Antibiotic-associated Diarrhea

United States
Amgen

Completed

A Study to Assess the Effect of Avacopan at Therapeutic and Supratherapeutic Doses on the QT/QTc Interval in Healthy Participants

Electrocardiography

United States

Search clinical trials for: complement inhibitor

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in El Salvador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations